#BCL-2 inhibitors market

[healthcareporium]

https://www.delveinsight.com/report-store/bcl2-inhibitors-market-forecast?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr

BCL-2 inhibitors represent a promising class of anti-cancer therapeutics designed to target B-cell lymphoma-2 (BCL-2) proteins, which play a crucial role in regulating apoptosis or programmed cell death.

[bommagoni]

BCL-2 (B-cell lymphoma 2) Inhibitor Market Growth Insights

[health-views-updates]

Advances in Leukemia Therapeutics: Innovations and Emerging Trends

The Evolving Landscape of Leukemia Treatment

Leukemia, a group of malignancies that affect the blood and bone marrow, continues to challenge the medical community with its complexity and variability. Recent years have seen significant strides in leukemia therapeutics, driven by advancements in drug development, personalized medicine, and novel therapeutic strategies. These innovations are transforming treatment paradigms, offering new hope to patients and paving the way for more effective and targeted therapies.

Breakthroughs in Drug Development

One of the most significant advancements in leukemia therapeutics is the development of targeted therapies. Unlike traditional chemotherapy, which indiscriminately kills rapidly dividing cells, targeted therapies are designed to attack specific molecules involved in cancer progression. For instance, tyrosine kinase inhibitors (TKIs) like imatinib, dasatinib, and nilotinib have revolutionized the treatment of chronic myeloid leukemia (CML). These drugs target the BCR-ABL protein, a key driver of CML, leading to improved outcomes and reduced side effects compared to conventional treatments.

In addition to TKIs, the approval of novel agents such as venetoclax has marked a significant leap forward. Venetoclax targets the BCL-2 protein, which is often overexpressed in leukemia cells, thereby promoting their survival. By inhibiting BCL-2, venetoclax enhances the effectiveness of chemotherapy and has shown promise in treating acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).

Advances in Immunotherapy

Immunotherapy is another area where substantial progress has been made. Chimeric antigen receptor (CAR) T-cell therapy represents a groundbreaking approach, especially for acute lymphoblastic leukemia (ALL) and some cases of CLL. This therapy involves modifying a patient's T-cells to express a CAR that targets leukemia-specific antigens. The modified T-cells are then reintroduced into the patient’s body, where they identify and destroy leukemia cells.

Recent studies have demonstrated the efficacy of CAR T-cell therapies, leading to impressive remission rates in patients with refractory or relapsed leukemia. However, this approach is not without challenges. The risk of cytokine release syndrome (CRS) and neurotoxicity remains a concern, and ongoing research aims to enhance the safety and effectiveness of CAR T-cell therapies.

The Leukemia Therapeutics Market size was USD 16 Billion in 2023 and is expected to Reach USD 27.28 Billion by 2031 and grow at a CAGR of 6.9% over the forecast period of 2024-2031.

Precision Medicine and Genetic Insights

The era of precision medicine has ushered in a new approach to leukemia treatment, with a focus on tailoring therapies based on individual genetic profiles. Advances in genomic sequencing have identified specific mutations and genetic alterations associated with different types of leukemia. For example, mutations in the FLT3 gene are common in AML, and targeted inhibitors like midostaurin are being used to address these mutations.

Similarly, research into the genetic underpinnings of CLL has led to the development of drugs that target specific mutations or pathways involved in the disease. By understanding the unique genetic landscape of each patient’s leukemia, clinicians can select the most effective therapies and potentially improve treatment outcomes.

Future Directions and Challenges

While the progress in leukemia therapeutics is promising, several challenges remain. The high cost of novel therapies, including CAR T-cell treatments, poses a significant barrier to access for many patients. Additionally, the development of resistance to targeted therapies and immunotherapies requires ongoing research to develop new and effective treatment options.

Looking ahead, researchers are exploring combination therapies, novel drug targets, and personalized approaches to overcome these challenges. The integration of artificial intelligence and machine learning in drug discovery and treatment planning holds the potential to further accelerate progress in leukemia therapeutics.

Conclusion

The field of leukemia therapeutics is undergoing a transformative phase, with innovations in drug development, immunotherapy, and precision medicine leading the way. These advancements are not only enhancing treatment outcomes but also offering new hope to patients. As research continues to evolve, the focus will remain on overcoming current challenges and pushing the boundaries of what is possible in the fight against leukemia.

[market-analysis]

BCL-2 (B-cell lymphoma 2) Inhibitors Market is estimated to value over USD xx billion by 2027 end and register a CAGR of xx% from the forecast period 2020-2027.

The report initiates from the outline of business surroundings and explains the commercial summary of chain structure. Moreover, it analyses By Indication Type, By Product, By End-User, By Region and BCL-2 (B-cell lymphoma 2) Inhibitors Market.

[techscimarketresearch]

Senolytic Drugs Market to Grow with Impressive CAGR During the Forecast Period | TechSci Research

Global Senolytic Drugs Market is driven by advancing pharmaceutical industry in the forecast period, 2023-2027.

According to TechSci Research report, “Senolytic Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027”, the global senolytic drugs market has a potential to project an impressive CAGR toward forces growth in the period, 2023-2027, on the account of increasing demand for anti-aging drugs. Rapidly advancing healthcare sector and expanding pharmaceutical industry is further responsible for the growth of the global senolytic drugs market in the upcoming five years.

Surge in the demand for the advanced pharmaceutical and therapeutics in the major economies is further anticipated to support the growth of the global senolytic drugs market in the next five years. Multiple market players have invested in research and rapidly increasing their financial supports to the research institutes and academic center dedicated toward designing anti-aging drugs and senolytic drugs thus substantiating the growth of the global senolytic drugs market in the future five years.

Increasing instances of chronic diseases like cardiovascular diseases, neurodegenerative diseases, chronic obtrusive pulmonary diseases (COPD), etc. is also raising the demand for the senolytic drugs thus aiding the growth of the global senolytic drugs market in the forecast years, until 2027. Rapidly growing cases of geriatric population suffering from high blood pressure, diabetes, Alzheimer disease and Parkinson disease, are related to the growing age among humans.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Senolytic Drugs Market"

https://www.techsciresearch.com/report/senolytic-drugs-market/8205.html

With increasing geriatric population of the world that may exceed 1 billion counts in next 30 years is also one of the major reasons behind futuristic growth of the global senolytic drugs market in the upcoming five years.

Although, stringent rules and regulations regarding FDA approvals and clinical trials on the developing senolytic drugs may put mild restraint on the growth of the global senolytic drugs market in the future.

The global senolytic drugs market segmentation is based on type, application, distribution channel, regional distribution, and competitive landscape. Based on type, the market is fragmented into FOXO4-related peptides, bcl-2 Family Inhibitors, Src Tyrosine Kinase Inhibitors, Navitoclax, Dasatinib & Quercetin, and others. Dasatinib, Quercetin, Fisetin and Navitoclax are some of the primarily discovered senolytic drugs through hypothesis.

Pre-clinical functions of the of the senolytic drugs were designed to be preventive toward cancers, and cardiovascular, neuropsychiatric, liver, kidney, musculoskeletal, lung, eye, hematological, metabolic and skin disorders. Also, clinical trials of these drugs against diabetes, idiopathic pulmonary fibrosis, Alzheimer’s disease, COVID-19, osteoarthritis, osteoporosis, eye disease, etc. are continued. The studies are still being conducted and commercialization of these drugs have still not started.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=8205 Customers can also request for 10% free customization on this report.

Market segmentation based on application, bifurcates into longevity, senescence inhibition, cardiovascular diseases, neural degenerative diseases, and others. Longevity is anticipated to hold the largest revenue shares of the market and dominate the market segment in the upcoming five years on the account of increasing demand for the pharmaceutical products that can aid healthy lifespan in humans. Rapidly increasing geriatric population of the world is further driving the growth of the global senolytic drugs market in the next five years.

Senescence inhibition is the process of killing the aged cells that are not dividing and accumulating in a location forming tumorous lump. Usually, senescence in cells is a stress response mechanism induced by different type of bodily responses like telomere attrition, DNA damage, and oncogenic mutations, etc. Available therapeutics target such senescent cells act on specific killing of these cells by senolytic process, specific inhibition of the secretory phenotype, and improving removal of senescent cells by immune system.

Some of the market players, dominating the global senolytic drugs market are:

AgeX Therapeutics, Inc.

Cleara Biotech

Eternans Ltd.

FoxBio Inc

Numeric Biotech

T.A. Sciences, Inc.

Recursion Pharmaceuticals, Inc.

The existing market players are highly invested in research and product development along with viable service provisions for the consumers. New market entrants may follow similar strategies along with merger and acquisition methods for future brand establishment.

Press Release: https://www.techsciresearch.com/news/6824-senolytic-drugs-market.html

“North America is anticipated to hold the largest revenue shares of the market and dominate the regional analysis in the upcoming five years on the account of expanding healthcare industry in the region. In the major economies like the United States, and Canada, healthcare sector is booming on the basis of increasing research and advancement in the pharmaceutical sector in the countries along with the increasing investment in the pharmaceutical designing, production and further research over senescent cells. Moreover, government aid along with the FDA approvals for the senolytic drugs is further anticipated to aid the growth of the global senolytic drugs market in the next five years,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Senolytic Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027 Segmented By Type (FOXO4-related peptides, bcl-2 Family Inhibitors, Src Tyrosine Kinase Inhibitors, Navitoclax, Dasatinib & Quercetin, Others), By Application (Longevity, Senescence Inhibition, Cardiovascular Diseases, Neural Degenerative Diseases, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region”, has evaluated the future growth potential of global senolytic drugs and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global senolytic drugs market.

Browse Related Reports:

Global Anti-Fungal Drugs Market By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), By Indication (Candidiasis, Aspergillosis, Mucormycosis, Dermatophytosis, Others), By Infection Type (Superficial Fungal Infection, Systemic Fungal Infection), By Route of Administration (Topical, Oral, Parenteral, Others), By End User (Homecare, Hospitals, Clinics, Others) By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/anti-fungal-drugs-market/7786.html

Global Nuclear Medicine Market By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes), By Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals v/s PET Radiopharmaceuticals), By Therapeutic Nuclear Medicine (Alpha Emitters v/s Beta Emitters), By Application (Diagnostic Applications v/s Therapeutic Applications), By Diagnostic Applications (SPECT Applications v/s PET Applications), By Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Others), By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions), By Region, Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/nuclear-medicine-market/4562.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[techsciresearch]

Senolytic Drugs Market to Grow with Impressive CAGR During the Forecast Period | TechSci Research

Global Senolytic Drugs Market is driven by advancing pharmaceutical industry in the forecast period, 2023-2027.

According to TechSci Research report, “Senolytic Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027”, the global senolytic drugs market has a potential to project an impressive CAGR toward forces growth in the period, 2023-2027, on the account of increasing demand for anti-aging drugs. Rapidly advancing healthcare sector and expanding pharmaceutical industry is further responsible for the growth of the global senolytic drugs market in the upcoming five years.

Surge in the demand for the advanced pharmaceutical and therapeutics in the major economies is further anticipated to support the growth of the global senolytic drugs market in the next five years. Multiple market players have invested in research and rapidly increasing their financial supports to the research institutes and academic center dedicated toward designing anti-aging drugs and senolytic drugs thus substantiating the growth of the global senolytic drugs market in the future five years.

Increasing instances of chronic diseases like cardiovascular diseases, neurodegenerative diseases, chronic obtrusive pulmonary diseases (COPD), etc. is also raising the demand for the senolytic drugs thus aiding the growth of the global senolytic drugs market in the forecast years, until 2027. Rapidly growing cases of geriatric population suffering from high blood pressure, diabetes, Alzheimer disease and Parkinson disease, are related to the growing age among humans.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Senolytic Drugs Market"

https://www.techsciresearch.com/report/senolytic-drugs-market/8205.html

With increasing geriatric population of the world that may exceed 1 billion counts in next 30 years is also one of the major reasons behind futuristic growth of the global senolytic drugs market in the upcoming five years.

Although, stringent rules and regulations regarding FDA approvals and clinical trials on the developing senolytic drugs may put mild restraint on the growth of the global senolytic drugs market in the future.

The global senolytic drugs market segmentation is based on type, application, distribution channel, regional distribution, and competitive landscape. Based on type, the market is fragmented into FOXO4-related peptides, bcl-2 Family Inhibitors, Src Tyrosine Kinase Inhibitors, Navitoclax, Dasatinib & Quercetin, and others. Dasatinib, Quercetin, Fisetin and Navitoclax are some of the primarily discovered senolytic drugs through hypothesis.

Pre-clinical functions of the of the senolytic drugs were designed to be preventive toward cancers, and cardiovascular, neuropsychiatric, liver, kidney, musculoskeletal, lung, eye, hematological, metabolic and skin disorders. Also, clinical trials of these drugs against diabetes, idiopathic pulmonary fibrosis, Alzheimer’s disease, COVID-19, osteoarthritis, osteoporosis, eye disease, etc. are continued. The studies are still being conducted and commercialization of these drugs have still not started.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=8205 Customers can also request for 10% free customization on this report.

Market segmentation based on application, bifurcates into longevity, senescence inhibition, cardiovascular diseases, neural degenerative diseases, and others. Longevity is anticipated to hold the largest revenue shares of the market and dominate the market segment in the upcoming five years on the account of increasing demand for the pharmaceutical products that can aid healthy lifespan in humans. Rapidly increasing geriatric population of the world is further driving the growth of the global senolytic drugs market in the next five years.

Senescence inhibition is the process of killing the aged cells that are not dividing and accumulating in a location forming tumorous lump. Usually, senescence in cells is a stress response mechanism induced by different type of bodily responses like telomere attrition, DNA damage, and oncogenic mutations, etc. Available therapeutics target such senescent cells act on specific killing of these cells by senolytic process, specific inhibition of the secretory phenotype, and improving removal of senescent cells by immune system.

Some of the market players, dominating the global senolytic drugs market are:

AgeX Therapeutics, Inc.

Cleara Biotech

Eternans Ltd.

FoxBio Inc

Numeric Biotech

T.A. Sciences, Inc.

Recursion Pharmaceuticals, Inc.

The existing market players are highly invested in research and product development along with viable service provisions for the consumers. New market entrants may follow similar strategies along with merger and acquisition methods for future brand establishment.

Press Release: https://www.techsciresearch.com/news/6824-senolytic-drugs-market.html

“North America is anticipated to hold the largest revenue shares of the market and dominate the regional analysis in the upcoming five years on the account of expanding healthcare industry in the region. In the major economies like the United States, and Canada, healthcare sector is booming on the basis of increasing research and advancement in the pharmaceutical sector in the countries along with the increasing investment in the pharmaceutical designing, production and further research over senescent cells. Moreover, government aid along with the FDA approvals for the senolytic drugs is further anticipated to aid the growth of the global senolytic drugs market in the next five years,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Senolytic Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027 Segmented By Type (FOXO4-related peptides, bcl-2 Family Inhibitors, Src Tyrosine Kinase Inhibitors, Navitoclax, Dasatinib & Quercetin, Others), By Application (Longevity, Senescence Inhibition, Cardiovascular Diseases, Neural Degenerative Diseases, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region”, has evaluated the future growth potential of global senolytic drugs and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global senolytic drugs market.

Browse Related Reports:

Global Anti-Fungal Drugs Market By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), By Indication (Candidiasis, Aspergillosis, Mucormycosis, Dermatophytosis, Others), By Infection Type (Superficial Fungal Infection, Systemic Fungal Infection), By Route of Administration (Topical, Oral, Parenteral, Others), By End User (Homecare, Hospitals, Clinics, Others) By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/anti-fungal-drugs-market/7786.html

Global Nuclear Medicine Market By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes), By Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals v/s PET Radiopharmaceuticals), By Therapeutic Nuclear Medicine (Alpha Emitters v/s Beta Emitters), By Application (Diagnostic Applications v/s Therapeutic Applications), By Diagnostic Applications (SPECT Applications v/s PET Applications), By Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Others), By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions), By Region, Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/nuclear-medicine-market/4562.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[healthcare-market]

BCL-2 (B-cell lymphoma 2) Inhibitors Market Trends and Forecast up to 2027

BCL-2 (B-cell lymphoma 2) Inhibitors Market: Introduction

· BCL-2, also known as B Cell Lymphoma 2, is a protein encoding gene belonging to the B cell lymphoma family. This protein is considered to be an outer mitochondrial protein membrane, which functions as a signaling pathway to further control the mitochondrial permeability against the apoptotic stimuli response. Aberrant expression and translocation of chromosomes are considered to be cancer symptoms in various tissues. The BCL-2 family comprise the 25-apoptotic and anti-apoptotic members that maintain a balance between new forming cells and old dying cells.

· Venetoclax is the only and fist approved FDA BCL-2 inhibitor drug for chronic lymphocytic lymphoma (CLL) patients. Although various clinical trials are being carried out for the development of new BCL-2 inhibitors.

Read Report Overview: https://www.transparencymarketresearch.com/bcl-2-b-cell-lymphoma-2-inhibitors-market.html

Get an Idea about the Offerings of Our BCL-2 (B-cell lymphoma 2) Inhibitors Market Report from this Brochure

Key Drivers and Restraints of Global BCL-2 (B-cell lymphoma 2) Inhibitors Market

· There is a rise in the prevalence of Diffuse B cell Lymphoma (DLBCL), a common type of non-Hodgkin lymphoma. As per Lymphoma Research Foundation article, in 2019, in the U.S., DLBCL accounted for 22% of new diagnosed B cell lymphoma cases. Each year, 18,000 people are diagnosed with DLBCL globally. This B cell lymphoma affects people over 60 years of age. As per the American Cancer Society's, in the year 2019, 20,720 people are estimated to be diagnosed with CLL. Moreover, 90% of the people diagnosed with CLL are estimated to affecting people above 50 years of age. In the U.S., 2,220 men and 1,710 women are expected to be suffering from CLL every year. Moreover, as per the American Cancer Society, about 3,930 death are expected to take place in 2019.

Request a Sample of BCL-2 (B-cell lymphoma 2) Inhibitors Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=72958

· Governments of developed and developing countries are initiating awareness campaigns to reduce mortality and morbidity rates. This is expected to boost the demand in the effective cancer treatment. For instance, Public Health England, an executive agency of the Department of Health in the U.K., started “Be Clear on Cancer” campaign aimed at improving early diagnosis of cancer by holding the public awareness program. In April 2016, the U.S. Government allocated US$ 5.2 Bn for the National Cancer Institute (NCI), a Federal Government agency, for cancer research and training. The budget increased by 5.3% as compared to the previous year. NCI conducts clinical trials on cancer patients who require repetitive diagnosis to check the prognosis of cancer.

· Availability of BCl-2 inhibitors is limited, the first and only approved drug for the BCL 2 inhibitor is Venetoclax. The FDA approved this drug as a second line treatment for CLL. This limits the availability of treatment to physicians and patients globally.

Enquiry before Buying BCL-2 (B-cell lymphoma 2) Inhibitors Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=52958

Combination Therapy a Preferred Treatment for CLL

· Venetoclax is the only selective inhibitor of the BCL-2 for the relapsed /refractory CLL with 17p deletion depending on the high response rate and safety profile. The inhibitor belongs to the BH3-mimetics class, which is an emerging and novel compound class for the treatment of the BCL-2 indication.

· Various clinical settings have proved the combination of Venetoclax with other compounds successful in treating the BCL-2 indication. Venetoclax is expected to be used in combination with other agents. As compared to monotherapy, the usage of Venetoclax in combination with other drugs reduces adverse events in patients of nausea, diarrhea, thrombocytopenia, and others.

Pre-book BCL-2 (B-cell lymphoma 2) Inhibitors Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=72958&ltype=S

North America to Lead Global BCL-2 (B-cell lymphoma 2) Inhibitors Market

· In terms of region, the global BCL-2 (B-cell lymphoma 2) inhibitors market can be divided into: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

· North America is expected to lead the global BCL-2 Inhibitors market, owing to rising cases of CLL and hematology malignancies patient pool. Moreover, approval for Venetoclax in the region, along with combination with other drugs is likely to the drive the market in the region. Ongoing strategic collaborations are also anticipated to fuel the development of the North America BCL-2 inhibitors market. Technological advancement and investments in research & development will propel the market in the region.

· Campaigns for creating awareness about CLL and treatments are likely to boost the demand for BCL-2 inhibitors

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/players-in-pressure-relief-devices-market-lean-on-launching-smart-therapeutic-beds-for-preventing-pressure-injuries-in-patients-market-valuation-to-reach-us-4-54-bn-by-2030--finds-tmr-301349292.html

https://www.prnewswire.com/news-releases/urgent-care-centers-market-valuation-to-reach-us-35-4-bn-by-2027-due-to-increased-access-to-healthcare-low-cost-of-treatment-finds-a-tmr-study-301355857.html

https://www.prnewswire.com/news-releases/rise-in-prevalence-of-dry-eye-disease-due-to-ageing-use-of-computers-to-drive-dry-eye-disease-treatment-market-says-tmr-301360562.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com

[kritikarehani]

Acute Myeloid Leukemia Market Size, Share, Trends, Epidemiology and Market Forecast 2030

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous malignancy characterized through clonal proliferation and impaired differentiation of myeloid precursors with various outcomes. Quickest-growing cancer happens when the bone marrow begins to form cells that have not yet absolutely matured as blasts. These cells crowd the bone marrow, stopping it from making normal blood cells and leukemia starts to crowd out the normal white blood cells, crimson blood cells, and platelets that the frame desires. In Acute myeloid leukemia, the bone marrow additionally makes strange crimson cells and platelets. As consequence, the blood cells do not develop, and it gets hard to ward off infections.

Acute Myeloid Leukemia Signs and Symptoms

The symptoms of acute myeloid leukemia generally expand over a week and become an increasing number severely. Signs can include anemia, light skin, constant tiredness, joint infections, frequent bleeding, bone pain, and others.

Acute Myeloid Leukemia Epidemiology

Acute Myeloid Leukemia accounts for <3% of all cancer, and 25% of all leukemia in adults. Worldwide, the incidence of Acute Myeloid Leukemia is reported to be highest in the US, Australia, and Western Europe. The incidence has been near stable over the last years. Incidence continuously shows 2 peaks in occurrence in early childhood and later adulthood. From 2000 to 2003, the US incidence rate in people aged <65 years was only 1.8 per 100,000 persons, whereas the incidence rate in people aged 65 years was 17 per 100,000 persons.

The Acute Myeloid Leukemia incidence rate of 3.7 per 100,000 inhabitants in Europe with a 5-year survival rate of 19%. A cross-national study using US and England data found that the overall risk of mortality for Acute Myeloid Leukemia was 23% lower in England compared to that in the US. However, survival difference was similar in subgroups of sex and age at diagnosis.

According to a study, the yearly average incidence rate of leukemia was 3.68/105 during 2003-2007 in Nanjing. There were no significant differences in gender, the incidence rate was the highest in the group aged 80~ years.

Acute Myeloid Leukemia Treatment Options

Acute Myeloid Leukemia is common leukemia affecting adults and poses a major medical challenge with increased mortality and morbidity. Once diagnosed, the treatment needs to start as quickly as possible. The treatment depends on age, risk factors, and the sub-types of Acute Myeloid Leukemia.

The aim of treatment for Acute Myeloid Leukemia is to cure it and achieve remission of leukemia cells. Traditionally, the standardized treatment was chemotherapy which can be divided into intensive chemotherapy and non-intensive. The intensive chemotherapies are two phases of remission induction followed by post-remission consolidation-based therapy. The induction therapy includes drugs such as Cytarabine, Daunorubicin, Idarubicin, and Fludarabine either alone or in combinatorial doses. Consolidation therapy is presented in such cases where induction therapy failed to work, with drugs such as Etoposide, Amsacrine, and Mitoxantrone.

Acute Myeloid Leukemia Market

FLT3 Inhibitors such as Midostaurin and Gilteritinib; IDH Inhibitors such as Enasidenib and Ivosidenib; and Hedgehog pathway inhibitor, such as Glasdegib; BCL-2 inhibitor such as Venetoclax have recently entered the Acute Myeloid Leukemia market as promising targeted therapies with specific genetic mutations. As the first directed agent that works very well in the elderly population with Acute Myeloid Leukemia, Venetoclax and Glasdegib has opened possibilities in the world of targeted therapy. Gilteritinib, Enasidenib, and Ivosidenib were approved explicitly for relapsed and refractory Acute Myeloid Leukemia, with specific genetic mutations. This spell of new drug approvals has altered the Acute Myeloid Leukemia Market and provided new opportunities.

Various companies such as Actinium Pharmaceuticals, AVEO Oncology, Biodesix, Daiichi Sankyo, BioSight, Helsinn Healthcare, Rafael Pharmaceuticals, Otsuka Pharmaceutical, Cyclacel Pharmaceuticals, and others are developing effective therapies, which contribute to the market size of Acute Myeloid Leukemia.  

There are many competitors in the development phase for the treatment of AML such as Iomab-B CD45 and Actimab-A CD33 (Actinium Pharmaceuticals), Ficlatuzumab (AVEO Oncology and Biodesix), Devimistat (Rafael Pharmaceuticals), BST236 (BioSight), Bemcentinib (BerGenBio), Pracinostat (Helsinn Healthcare) and others.

[adityarana1687-blog]

Apoptosis Assay Market Anticipated To Achieve Lucrative Growth Worth $2.3 Billion By 2027

The global apoptosis assay market size is expected to reach USD 7.5 billion by 2027, expanding at a CAGR of 7.6%, according to a new report by Grand View Research, Inc. Extensive research activities on expanding applications of drug-induced apoptosis assays have propelled the inclination of pharmaceutical manufacturers towards incorporating cell cycle products in the drug discovery and designing process.

The introduction of affordable and easy to perform kits that can be accommodated in complex experiments is expected to minimize the overhead costs of apoptosis experiments. Companies are providing highly precise reagents and lot-to-lot reproducibility in sample measurements.

Professionals at pharmaceutical companies are making use of cell-cycle inhibitors and Apoptosis-Inducing Factors (AIF)/ molecules to explore possible drug targets. Also, high demand for caspase activity assays along with Bcl-2 protein family across pharmaceutical companies for apoptosis detection has been observed in recent years. Biotechnology companies are enhancing quantification techniques to enable real-time monitoring of apoptotic cellular dynamics.

The presence of established guidelines and protocols for cell-potency assays has strengthened the development of efficient cell-death detection assays. Whereas, stringent regulations with respect to the approval of cell-potency assays are ensuring successful uptake of market products launched.

The flow cytometry segment dominated the market and accounted for the largest revenue share in 2019. This is attributed to the increasing adoption of the technique among researchers. It helps in finding the difference between intact mitochondria (healthy cells) and permeabilized mitochondria (cells undergoing death). The segment is anticipated to grow fast over the forecast period.

The pharmaceutical and biotechnology segment dominated the market in 2019 and is anticipated to continue its dominance over the forecast period. This is attributed to the rising incidence of cancer and neurodegenerative disorders. In addition, the growing significance of programmed cell death or apoptosis to treat chronic diseases is driving the segment growth.

Request a free sample copy or view report summary: Apoptosis Assay Market Report

Apoptosis Assay Market Report Highlights

The kits segment dominated the market and accounted for a revenue share of around 50.0% owing to increasing investment by key market players

Increase in the demand for fluorochrome-labeled inhibitors of caspases has made reagents the fastest growing product segment in the market

Application of these inhibitors with other techniques is anticipated to enhance the apoptosis assessment, thereby driving segment growth

Owing to the wide adoption and easy availability of products, flow cytometry is estimated to account for a substantial share of approximately 35.0% in 2019

The increasing significance of continuous monitoring of programmed cell death across novel drug discoveries and development of advanced therapeutics is set to propel market growth

North America has dominated the market in terms of revenue share in 2019, and Asia Pacific is expected to witness the fastest growth in the coming years as a result of the expanding CRO landscape in the region

Key companies are competing in terms of a combination of products and services in order to maintain market share.

Apoptosis Assay Market Segmentation

Grand View Research has segmented the global apoptosis assay market on the basis of product, technique, assay type, end-use, and region:

Apoptosis Assay Product Outlook (Revenue, USD Million, 2016 - 2027)

Kits

Reagents

Instruments

Apoptosis Assay Technique Outlook (Revenue, USD Million, 2016 - 2027)

Flow Cytometry

Fluorescence Microscopy

Spectrophotometry

Other Techniques

Apoptosis Assay Type Outlook (Revenue, USD Million, 2016 - 2027)

Caspase

DNA Fragmentation

Cell Permeability

Mitochondrial

Apoptosis Assay End-use Outlook (Revenue, USD Million, 2016 - 2027)

Pharmaceutical & Biotechnology Companies

Hospital & Diagnostic Laboratories

Academic & Research Institutes

Apoptosis Assay Regional Outlook (Revenue, USD Million, 2016 - 2027)

North America

Europe

Asia Pacific

Latin America

MEA

The U.S.

Canada

Germany

The U.K.

France

Italy

Spain

Japan

China

India

Brazil

Mexico

South Africa

Saudi Arabia

List of Key Players of Apoptosis Assay Market

Thermo Fisher Scientific, Inc.

Bio-Rad Laboratories

Bio-Techne

Biotium

GeneCopoeia, Inc.

Becton, Dickinson & Company (BD)

Thermo Fisher Scientific, Inc.

Promega Corporation

Sartorius AG

Merck KGaA

Abcam plc.

Takara Bio Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

[riyaus]

cancer biologics Market 2021-2029

cancer biologics Market 2021

The global cancer biologics market was valued at USD 31,179.71 million in 2019 and is expected to grow at 6.7% CAGR during the forecast study period, and is expected to reach USD 1789.59 million.

The biologic drug is a product produced from living organisms and includes various products derived from animals, humans, or microorganisms by using biotechnology. Types of biologics drugs include blood, vaccines, cells, allergens, tissues, genes, and recombinant proteins. These drugs alter the method of operation of natural biologic cellular and intracellular actions.

Get a  Sample copy of this report :   https://straitsresearch.com/report/cancer biologics-Market/request-sample

Key Market Players

Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly and Company, Sanofi, CELGENE CORPORATION, Pfizer Inc., Bayer AG, Johnson and Johnson Services, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., and Amgen Inc.

Recent Developments

In December 2019, Biocon and its partner Mylan collaboratively launched a cancer drug Ogivri, a biosimilar to Herceptin, in the U.S. The drug is available in a 420mg multi-dose vial and a 150mg single-dose vial to treat all types of breast cancer and metastatic stomach cancer. In November 2018, Roche and Abbvie received FDA approval for Venclexta, a BCL-2 inhibitor effective in treating leukemia. Venclexta is jointly commercialized by Abbvie and Genetech, a part of Roche.

[pharmaphorumuk]

AbbVie, J&J embed Imbruvica deeper in CLL therapy with new approval

AbbVie and Johnson & Johnson’s Imbruvica is already a mainstay of chronic lymphocytic leukaemia (CLL) therapy, but can now be used as part of a chemotherapy-free regimen for younger patients in the US.

The FDA has just approved its eleventh indication for BTK inhibitor Imbruvica (ibrutinib), making it an option with Roche’s Rituxan (rituximab) for newly-diagnosed patients aged 70 or below with CLL or another cancer – small lymphocytic lymphoma – who are new to therapy.

Rituxan is already approved alongside chemotherapy drugs fludarabine and cyclophosphamide in this patient group, and has been a standard of care for younger, previously-untreated CLL patients for years.

The new regimen with Imbruvica does away with the chemotherapy element – which carries a high risk of debilitating side effects – and improves efficacy, according to Dr Brian Koffman, chief medical officer of the CLL Society medical charity.

Imbruvica monotherapy has become a mainstay of first-line treatment for older patients less able to tolerate chemo, and the drug has also been approved in the US and Europe as a chemotherapy-free option alongside Roche’s Rituxan follow-up Gazyva (obinutuzumab).

However, the new indication means it is now an option for CLL patients right across the board.

In the E1912 study which formed the basis of FDA approval, patients treated with Imbruvica plus Rituxan – an anti-CD20 antibody – lived longer with disease progression compared to Rituxan plus chemo. After 37 months, the progression-free survival (PFS) rate was 88% for the Imbruvica group and 75% for the chemo arm.

There are also signs of an improvement in overall survival, although at the latest 49-month data point that endpoint still had not been reached, with 11 deaths (3%) with Imbruvica and 12 (7%) in the chemo arm.

Imbruvica also seemed to be well tolerated by the majority of patients, with only 14% of them having stopped therapy due to side effects and 75% of them staying on the drug after four years’ follow-up.

The new approval consolidates Imbruvica’s position in CLL, which is co-marketed by J&J and AbbVie and made sales of $2.61 billion and $3.59 billion respectively for the partners last year.

The drug is however facing increased competition from AstraZeneca’s Calquence (acalabrutinib), which claimed FDA approval in first-line CLL last year, with BeiGene’s Brukinsa (zanubrutinib) also emerging as a potential challenger although not yet in CLL.

AbbVie is also running the CAPTIVATE trial of its BCL-2 inhibitor Venclexta (venetoclax) with Imbruvica which could provide yet another front-line option for CLL patients.

The post AbbVie, J&J embed Imbruvica deeper in CLL therapy with new approval appeared first on .

from https://pharmaphorum.com/news/abbvie-jj-embed-imbruvica-deeper-in-cll-therapy-with-new-approval/

[kisan512posts]

Apoptosis -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2022

Apoptosis Industry

Description

Wiseguyreports.Com Adds “Apoptosis -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database

Apoptosis Market research report gives an insight into Apoptosis Mechanism, by Molecular Pathways, Caspase Activators and Inhibitors, Protease/Proteasome Inhibitors, Bcl-2 Modulators, p53 Modulators and Other. The study also focuses on major diseases for which the treatment is based on apoptosis comprising Cancer, Neurodegenerative Diseases, Cardiovascular Diseases and other apoptosis based diseases including HIV infection, Organ Transplant Rejection and MODS. The study provides apoptosis market size related therapeutic products by the above apoptosis molecular pathways and also by the disease areas. The study includes estimates and projections for the total global apoptosis related therapeutic products market. Projections and estimates are also graphically illustrated by geographic regions encompassing North America, Europe, Asia-Pacific and Rest of World. Business profiles of 58 major companies are discussed in the report. The report serves as a guide to global apoptosis market, covering more than 555 companies that are engaged in apoptosis research, testing and supply of products and services. Major Contract Research Organizations and Universities serving apoptosis market are also covered in the Corporate Directory section of this report. Information related product developments, partnerships, collaborations, and mergers and acquisitions are also covered in the report. Compilation of Worldwide Patents and Research related to Apoptosis is provided.

OUR NEW SAMPLE HAVE BEEN UPDATED NOW WHICH CORRESPOND IN NEW REPORT SHOWING IMPACT OF COVID-19 ON INDUSTRY

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/30787-apoptosis-market-research-report

Over the past few years, availability of apoptosis related products (drugs, kits and reagents) has increased enormously. Global market for apoptosis related products is expected to grow at a high CAGR of 31.2% through 2005-2020, and the high growth is owing to increasing evidence of role of apoptosis in mechanism of action for large number of diseases such as Cancer; Neurodegenerative Diseases including Alzheimer’s, Parkinson’s, Multiple Sclerosis and Rheumatoid Arthritis; Cardiovascular Disease; and other apoptosis based diseases including organ transplant rejection and HIV infection. Cancer research has delivered outstanding progress in understanding the biology and genomics of cancer, in the last decade. Foremost of these progress areas is the recognition of apoptosis and its regulatory genes that have an effect on melanoma. In return, other oncogenical changes stimulate apoptosis and override apoptosis during multistage carcinogenesis by making selective pressures. Apoptosis associates cancer therapeutics with cancer genetics by providing conceptual structure, as well as similar changes that suppress apoptosis during tumor development.

Why Buy This Report?

This report may help Strategists, Investors, Laboratories, Contract Research Organizations, Biotechnology & Healthcare Companies, Academic Professionals, Drug Approval Authorities, and Other Organizations to –

Identify Market Opportunities

Review and Analyze Global and Regional Markets

Gauge Market Potential for your Products

Identify Competition

Use Market Research for exploring new areas

Acquire Meaningful Guidelines for Strategic Planning

Gear up for Market Entry

Get Actionable Information

Leave a Query @ https://www.wiseguyreports.com/enquiry/30787-apoptosis-market-research-report

Analytics and data presented in each report pertain to several parameters such as –

Global and Regional Market Sizes, Market Shares, Market Trends

Product (Global and Regional) Market Sizes, Market Shares, Market Trends

Technology Trends

Corporate Intelligence

Key Companies By Sales, Brands, Products

Other Strategic Business Affecting Data

Companies Discussed

50+ Apoptosis Company Insight Profiles

555+ Company Directory Listing

Company Insight Profiles List

Abbott Laboratories (USA)

AbGenomics International (USA)

Aegera Therapeutics, Inc. (Canada)

Æterna Zentaris, Inc. (Canada)

AG Scientific, Inc. (USA)

Amarantus Therapeutics, Inc. (USA)

Amgen, Inc. (USA)

Anavex Life Sciences Corp. (USA)

Antisoma plc (UK)

Aposense Ltd. (Israel)

ArQule, Inc. (USA)

Ascenta Therapeutics, Inc. (USA)

Bayer Schering Pharma AG (Germany)

BD Biosciences (USA)

BioLineRx Ltd. (Israel)

Bioniche Life Sciences Inc. (Canada)

Chroma Therapeutics Ltd. (UK)

Cleveland BioLabs, Inc. (USA)

Critical Outcome Technologies, Inc. (UK)

Cyclacel Pharmaceuticals, Inc. (USA)

D-Pharm Ltd. (Israel)

EntreMed, Inc. (USA)

EpiCept Corporation (USA)

Exelixis, Inc. (USA)

F.Hoffmann-La Roche Ltd. (Switzerland)

GANYMED Pharmaceuticals AG (Germany)

Genentech, Inc. (USA)

Genmab A/S (Denmark)

Genzyme Corporation (USA)

GlaxoSmithKline plc (UK)

Incyte Corporation (USA)

Infinity Pharmaceuticals, Inc. (USA)

Keryx Biopharmaceuticals Inc (USA)

Life Technologies Corporation (USA)

MEI Pharma, Inc. (USA)

MorphoSys AG (Germany)

multimmune GmbH (Germany)

Neuren Pharmaceuticals Limited (New Zealand)

Novartis AG (Switzerland)

Novogen Limited (Australia)

Peregrine Pharmaceuticals, Inc. (USA)

Pfizer, Inc. (USA)

Pharmacyclics, Inc. (USA)

Sigma-Aldrich Co. LLC (USA)

Sunesis Pharmaceuticals, Inc. (USA)

Takeda Pharmaceutical Co., Ltd. (Japan)

Tamir Biotechnology, Inc. (USA)

TetraLogic Pharmaceuticals (USA)

The Institute of Cancer Research (UK)

ZELTIQ (USA)

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=30787

Continued…                                                                                                    

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (US)  Ph: +44 208 133 9349 (UK)

NOTE : Our final report have added the analysis of the impact of COVID-19 on this industry, Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

[databridgemarketresearchblog]

Global Blood Cancer Drug Market Size, Share and Growth Opportunities by 2026

Market Analysis: Global Blood Cancer Drug Market

Global blood cancer drug market is expected to rise gradually to an estimated to register a healthy CAGR of 10.5 % in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. Growing cases of hematology-oncology disorders and progressively focusing on innovation of novel therapies are the key drivers for market growth.

Few of the major competitors currently working in the global blood cancer drug market are Eli Lilly and Company, Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc, Johnson & Johnson Services. Inc., AbbVie Inc., Amgen Inc. , Bayer AG, Pfizer Inc., AstraZeneca, CELGNE CORPORATION, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, UCB SA, Sumitomo Dainippon Pharma Co., Ltd, Otsuka Holdings Co., Ltd, Astellas Pharma Inc. and many others..

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-blood-cancer-drug-market

Market Definition: Global Blood Cancer Drug Market

Blood cancer is life threatening oncology disorder in which cancer start growing in the bone marrow, where blood is produced. These tumors prevent the blood from functioning. The patients with blood cancer experience abdominal pain, bone pain, weight loss, dark spots, excessive or easy bruising and weakness. According to the statistic published in American Cancer Society 2019, it is estimated that over 8,110 cases are diagnosed with Hodgkin lymphoma in the United States in this current year. It is more prevalent in teenagers aged 15 to 19 years. Growing incidence of Hodgkin lymphoma worldwide and accelerating demand of clinical treatment and novel therapies indicates the significant growth of market.

Market Drivers

Rise in the incidence and prevalence rate of the disease will drive the growth of the market

Rise in the government and non-government investment in the research and development

Accelerating the demand of novel therapies and treatment

Increases in effectiveness of drugs for the treatment of hematology-oncology disorders

Market Restraints

Patent expiry of blockbuster drugs will result in generic and biosimilar competition

Effective treatment is either unavailable or costly

Inadequate knowledge of blood cancer in developing countries

Segmentation: Global Blood Cancer Drug Market

By Type

Leukemia

Lymphoma

Hodgkin Lymphoma Myeloma

Leukemia Lymphocytic Leukemias

Myeloid leukemias

Others

Acute Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Acute Myeloid Leukemia

Chronic Myeloid Leukemia

Myeloprolifeative Neoplasms

Systemic Mastocytosis

Hairy Cell Leukaemia (HCL)

Non-Hodgkin Lymphoma

Typical Myeloma

Bence Jones Myeloma

Non-Secretory Myeloma

Immunoglobulin M–Producing Multiple Myeloma

By Therapy Type

Chemotherapy

Immunotherapy

Radiation therapy

Targeted Therapy

By Treatment

Medication

Blood Transfusion

Surgery

By Mechanism of Action Type Proteasome Inhibitor

B-Cell Lymphoma-2 (BCL-2) Protein Inhibitor

Isocitrate Dehydrogenase-1 (IDH1) Inhibitor

Hedgehog Pathway Inhibitor

Anti-CD20 Antibody

Bone Marrow Transplantation

Hematopoietic Stem Cell Transplantation

Bortezomib

Imatinib mesylate

Midostaurin

Gilteritinib

Rituxima Kinase Inhibitor

Venetoclax

Ivosidenib

Enasidenib

Glasdegib

Rituximab

Ibritumomab

By Route of Administration

Oral

Injectable

Intramuscular

Subcutaneous

Intra-arterial

Intravenous

By End users

Hospitals

Homecare

Specialty Clinics

Others

By Geography

North America

South America

Europe

Asia-Pacific

Middle East & Africa

U.S.

Canada

Mexico

Brazil

Argentina

Rest of South America

Germany

France

United Kingdom

Italy

Spain

Russia,

Turkey

Belgium

Netherlands

Switzerland

Rest of Europe

Japan

China

South Korea

India

Australia

Singapore

Thailand

Malaysia

Indonesia

Philippines

Rest of Asia Pacific

South Africa

Egypt

Saudi Arabia

United Arab Emirates

Israel

Rest of Middle East & Africa

Get TOC of Full Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-blood-cancer-drug-market

Key Developments in the Market:

In May 2019, AbbVie Inc. announced that they have received approval from FDA for Venclexta (venetoclax) which is an oral selective B-cell lymphoma-2 (BCL-2) protein inhibitor in combination with obinutuzumab for the treatment of chronic lymphocytic leukemia. With the approval of Venclexta expanded the company’s portfolio in therapeutic area of oncology

In March 2018, Novartis AG received the FDA expanded label approval of Tasigna (nilotinib), a kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP) in pediatric patients of age one year or older. This approval broaden the clinical indication of Tasigna

Competitive Analysis: Global Blood Cancer Drug Market

Global blood cancer drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of blood cancer market for global Europe, North America, Asia-Pacific, South America and Middle East & Africa.